Retatrutide 30mg
High-concentration Retatrutide for advanced research protocols requiring higher dosing flexibility. This 30mg formulation provides researchers with extended study duration capabilities and enhanced experimental design options.
| Quantity | Price | Discount |
|---|---|---|
| 2 | $412.25 | 3% |
| 5 | $399.50 | 6% |
| 10 | $378.25 | 11% |
| 11+ | $369.75 | 13% |
$425.00
What is Retatrutide?
Retatrutide (LY3437943) is an experimental peptide classified as a
triple agonist targeting the GIP (glucose-dependent insulinotropic polypeptide),
GLP-1 (glucagon-like peptide-1), and glucagon receptors.
This unique triple-action mechanism is designed to enhance insulin secretion, suppress appetite, regulate energy expenditure,
and promote significant weight loss while also improving glucose control.
Retatrutide Structure
| Peptide Name | Retatrutide |
|---|---|
| Synonyms | LY3437943 |
| Sequence | Synthetic peptide analog (39 amino acids, engineered for enhanced receptor affinity) |
| Molecular Formula | Not publicly disclosed in full detail |
| Molecular Weight | Approx. 4800–4900 g/mol (estimated) |
Retatrutide Research
1. Retatrutide and Obesity
Phase 2 clinical studies have demonstrated unprecedented reductions in body weight.
Participants achieved up to 24% weight loss at 48 weeks, surpassing most current anti-obesity therapies.
The triple agonist design appears to combine appetite suppression with increased energy expenditure.
2. Retatrutide and Type 2 Diabetes
Research suggests Retatrutide substantially lowers HbA1c, fasting glucose, and postprandial glucose levels.
Improvements in insulin sensitivity and beta-cell function have also been observed.
3. Cardiometabolic Effects
Preliminary data indicates positive effects on lipid metabolism, blood pressure, and inflammatory biomarkers.
These findings point to potential long-term cardiovascular protection.
Future Retatrutide Research
Future trials are focused on long-term outcomes for obesity and type 2 diabetes,
as well as potential benefits in fatty liver disease (NAFLD/NASH), cardiovascular risk reduction, and metabolic syndrome management.
Ongoing research may also evaluate Retatrutide in combination therapies for enhanced metabolic control.
Retatrutide Resources
- Jastreboff AM, et al. NEJM 2023 – “Triple Hormone Receptor Agonist Retatrutide in Obesity.”
- Lilly Clinical Trials – LY3437943 study results.
- American Diabetes Association – Updates on emerging incretin-based therapies.
Related Products
CJC-1295 w/ DAC – 5 mg (10 Vials/Kit)
Recently Viewed
Reviews
There are no reviews yet.